A Comparative Study of Ampicillin/Sulbactam Versus Moxifloxacin in the Treatment of Complicated Intra-abdominal Infections

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00952796

Enrollment

100

Registered

2009-08-06

Start date

2009-01-31

Completion date

2010-12-31

Last updated

2011-08-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intra-abdominal Infection

Keywords

intra-abdominal infection, moxifloxacin, ampicillin/sulbactam

Brief summary

On the basis of monotherapy for intra-abdominal infection, the investigators are conducting this study to identify the difference of drug efficacy between ampicillin/sulbactam and moxifloxacin.

Interventions

DRUGmoxifloxacin

moxifloxacin 400mg once daily (IV form, 60minutes)

DRUGampicillin/sulbactam

ampicillin/sulbactam 1.5g 4 times daily (IV form, administered 60minutes)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Healthy volunteers

Inclusion criteria

* patients diagnosed of complicated intra-abdominal infection need surgical treatment

Exclusion criteria

* patients diagnosed of intra-abdominal infection receive non-operative management * patients with known allergic history of fluoroquinolone * Severe, life threatening disease with a life expectancy of \< 48 h or APS and APACHE scores of \> 35

Design outcomes

Primary

Measure	Time frame
clinical response at test-of-cure visit	test of cure: 10-14 days after initial treatment

Countries

Taiwan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026